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Islet cell transplantation is categorized as a β-cell replacement therapy for diabetic patients who lack the ability to secrete insulin. 
Allogeneic islet cell transplantation is for the treatment of type 1 diabetes, and autologous islet cell transplantation is for the pre-
vention of surgical diabetes after a total pancreatectomy. The issues of allogeneic islet cell transplantation include poor efficacy of 
islet isolation, the need for multiple donor pancreata, difficulty maintaining insulin independence and undesirable side effects of 
immunosuppressive drugs. Those issues have been solved step by step and allogeneic islet cell transplantation is almost ready to 
be the standard therapy. The donor shortage will be the next issue and marginal and/or living donor islet cell transplantation 
might alleviate the issue. Xeno-islet cell transplantation, β-cell regeneration from human stem cells and gene induction of the na-
ïve pancreas represent the next generation of β-cell replacement therapy. Autologous islet cell transplantation after total pancre-
atectomy for the treatment of chronic pancreatitis with severe abdominal pain is the standard therapy, even though only limited 
centers are able to perform this treatment. Remote center autologous islet cell transplantation is an attractive option for hospitals 
performing total pancreatectomies without the proper islet isolation facilities.
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INTRODUCTION
Islet cell transplantation is categorized as a β-cell replacement 
therapy for diabetic patients who lack the ability to secrete in-
sulin [1]. Islets possess their own glucose sensor, produce in-
sulin, release insulin in response to glucose, maintain normo-
glycemia, and function indefinitely [1]. Therefore, β-cell re-
placement by islet cell transplantation can reverse or prevent 
diabetes.
  The two types of clinical islet cell transplants that have been 
performed include allogeneic islet cell transplantation for the 
treatment of type 1 diabetes and autologous islet cell transplan-
tation for the prevention of surgical diabetes after a total pan-
createctomy.
  Allogeneic islet cell transplantation has several hurdles such 
as unstable outcomes of islet isolation, the need for multiple 
donor pancreata and transplants, difficulty maintaining insu-
lin independence, and detrimental side effects from immuno-
suppressants to be overcome before becoming a standard ther-
apy [1]. After the publication of the Edmonton protocol [2], 
clinical allogeneic islet cell transplantation has been substan-
tially improved over the past decade [3]. 
  On the other hand, autologous islet cell transplantation af-
ter total pancreatectomy for the treatment of chronic pancre-
atitis with intractable abdominal pain has become the standard 
therapy [4]. This treatment efficiently reduces abdominal pain 
by total pancreatectomy while avoiding brittle diabetes by au-
tologous islet cell transplantation.
  In this review article, current status and advances of both al-
logeneic and autologous islet cell transplantation are described.
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ALLOGENEIC ISLET CELL 
TRANSPLANTATION FOR THE TREATMENT 
OF TYPE 1 DIABETES
In 2000, the University of Alberta group published that 7 out 
of 7 type 1 diabetic patients became insulin independent after 
allogeneic islet cell transplantation [2]. The protocol of this pub-
lication was called the Edmonton protocol and this procedure 
was sensational because a minimally invasive cell therapy was 
able to reverse diabetes. After the publication of the Edmonton 
protocol, the number of clinical allogeneic islet cell transplan-
tation has increased [3]. When the Edmonton protocol was at-
tempted, some islet transplantation centers were able to dupli-
cate the outcomes [5] but other centers were not able to achieve 
similar success [6]. In order to confirm the results of the Ed-
monton protocol, a multi-center, international clinical trial was 
conducted [7]. This international, multi-center clinical trial 
revealed that achieving insulin independence after allogenic 
islet cell transplantation depended on a team of personnel pos-
sessing previous experience with islet isolation and islet cell 
transplantation. Islet isolation outcomes were not stable even 
at the advanced islet transplantation centers. The Edmonton 
protocol required two or more islet transplants because; the is-
let isolation process yielded unstable outcomes leading to inef-
ficient islet transplantation. Actually the study found that suc-
cess rate of islet isolation was 30% to 50%, therefore 4 to 6 do-
nor pancreata were necessary to achieve insulin independence 
for one type 1 diabetic patient. Thus, poor efficacy became one 
of the major issues of islet cell transplantation.
  In 2005, long-term clinical outcomes of the Edmonton pro-
tocol were published from the University of Alberta group [8]. 
This report demonstrated that approximately 80% of patients 
maintained viable transplanted islets; however, only less than 
10% of patients could maintain insulin independence 5 years 
after islet cell transplantation. The issue of maintaining insulin 
independence became another major challenge for clinical is-
let cell transplantation.
  Even though the Edmonton protocol avoids glucocorticoid 
steroid [2], other immunosuppressive drugs have side effects. 
One notable example is the combination of sirolimus and tacro-
limus, which damages renal function [9]. In addition, others 
and we have found that an islet cell transplantation recipient 
experiences an average of more than one serious adverse event 
(life-threatening or death) [3,10]. Deleterious side effects of im-
munosuppression are an additional issue of islet cell transplan-
tation.
  During this decade these issues have been widely addressed 
and significant improvements have been achieved.
ISSUES AND POTENTIAL SOLUTIONS FOR 
ALLOGENEIC ISLET CELL 
TRANSPLANTATION
Variable outcome of islet isolation
Even at the advanced islet transplantation centers, the outcome 
of human islet isolation varies [11,12]. The success of human 
islet isolation depends upon the quality of the donor, the pan-
creas preservation, the efficacy of pancreas digestion and islet 
purification. In order to increase the success rate of human is-
let isolations, each step needs to be improved.
  Pancreas donor criteria for successful islet isolation have 
been explored [13-16]. High body mass index, lack of fibrosis, 
and normal blood chemistry have shown to be the important 
factors for successful islet isolation.
  In terms of pancreas preservation, the two-layer pancreas 
preservation method has proven to be better than simple stor-
age with the University of Wisconsin solution [17-22]. How-
ever, the two-layer preservation method requires expertise when 
it is applied to human pancreas preservation [23-25]. Further-
more, the pancreatic duct also requires adequate preservation, 
because the pancreatic duct is used to perfuse collagenase for 
islet isolation. Pancreatic ductal injection was shown to protect 
the pancreatic duct effectively and improve the outcome of is-
let isolation [26-28].
  During the digestion step, over-digestion of isolated islets 
needs to be avoided. Trypsin inhibition could prevent over-di-
gestion [21,29]. However, the importance of trypsin inhibition 
is contentious when the donor pancreas is intact [30].
  Islet cells are purified by exploiting the density difference 
between islet cells and exocrine tissue. This density gradient is 
established by the COBE 2991 cell processor [1,2]. To generate 
the density gradient, Ficoll is generally used; however, Ficoll is 
not an ideal material due to its high viscosity and possible en-
dotoxin contamination [31,32]. Iodixanol, which was original-
ly developed for X-ray contrast, has been shown to be a better 
material for the density gradient solution [32-37].
  With the combination of the two-layer pancreas preserva-
tion, the pancreatic ductal injection by surgeons who belongs 
to islet isolation team and the iodixanol based density gradient, 
our success rate of human islet isolation is approximately 90% 201
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[38]. Hence unstable outcomes of islet isolation can be solved 
with current advanced methods.
Necessity of multiple transplants to achieve insulin 
independence
One of the drawbacks of the Edmonton protocol is the necessity 
of multiple donor pancreata and islet cell transplants to achieve 
insulin independence. However, the University of Minnesota 
group demonstrated that single donor islet cell transplantation 
to achieve insulin independence was possible using anti-inflam-
matory drugs combined with immunosuppression induction 
therapy using thymoglobulin [39]. We also reported successful 
single donor islet cell transplantation cases using an improved 
islet isolation method and potent anti-inflammatory drugs com-
bined with immunosuppression induction therapy using thy-
moglobulin [40,41]. Posselt et al. [42] demonstrated that 50% 
(4/8) of patients achieved insulin independence after single 
donor islet cell transplantation with immunosuppression in-
duction therapy using thymoglobulin combined with the anti-
LFA-1 antibody ‘efalizumab.’ Recently, the University of Alber-
ta group demonstrated that insulin and heparin infusions dur-
ing the peri-transplant period improved the success rate of 
single donor islet cell transplantation [43]. Taking these facts 
together, improved engraftments of transplanted islets in the 
early phase of transplantation should be the key for successful 
single donor islet cell transplantation. Immunosuppression in-
duction therapy using thymoglobulin, anti-inflammation 
therapy and supplements of insulin and heparin were impor-
tant strategies. In addition, the transplantation of many high 
quality islets should be the other important factor [40,41].
 
Issues with maintaining insulin independence
Poor long-term insulin independence was a great disappoint-
ment of the Edmonton protocol. Our recent survey of opinions 
from type 1 diabetic patients demonstrated that more than 80% 
of patients wished to become insulin independent [44]. Becom-
ing insulin independent is a strong motivating factor for accept-
ing islet cell transplantation.
  The University of Minnesota group demonstrated that 4 out 
of 6 patients maintained insulin independence at a mean of 3.4 
years after islet cell transplantation by immunosuppression in-
duction using thymoglobulin combined with anti-TNF alpha 
antibody treatment [45]. They transplanted an average of more 
than 11,000 islet equivalent (IEQ)/kg body weight using two 
pancreata for three cases and one pancreas for one case. Trans-
plantation of a high number of islet cells seems to be another 
important factor. The University of Miami group demonstrat-
ed that supplemental islet cell infusion with the GLP-1 analog 
‘exenatide’ and the anti-TNF alpha antibody ‘etanercept’ en-
abled them to achieve long-term insulin independence [46]. 
Under this protocol, four out of four patients achieved the 
long-term insulin independence (18 months). The average islet 
yield per body weight for the supplemental islet cell infusion 
was 5,613 IEQ/kg. Hence, adding a supplemental islet cell in-
fusion after an initially successful islet graft function fails 
should be an excellent strategy for achieving long-term insulin 
independence.
  In both the University of Minnesota and the University of 
Miami strategies, multiple islet cell transplants were necessary 
to maintain long-term insulin independence. Therefore, the 
timing of the additional islet cell transplants is important to 
maintain insulin independence. We demonstrated that main-
taining enough functional islet graft mass was associated with 
insulin independence [47]. We developed a new index (secre-
tory unit of islet transplant objects, SUITO index) which could 
reflect functional islet mass. The formula of the SUITO index 
is as follows: fasting C-peptide [ng/mL]/(fasting glucose [mg/
dL]-63)×1,500 [48,49]. A SUITO index of more than 26 was 
associated insulin independence. Therefore we postulated that 
when the SUITO index decreased and became close to 26, it 
was the appropriate time for a supplemental islet cell infusion. 
We experienced a unique case of prolonged insulin indepen-
dence (more than 2 years) in which a patient received total more 
than 20,000 IEQ/kg body weight after two islet cell transplants 
[49]. Her SUITO index remained higher than 30 for more than 
two years under the Edmonton type immunosuppression with-
out thymoglobulin induction. This case suggests that when a 
high quantity of islet cells is transplanted, prolonged insulin 
independence is achievable without the need for immunosup-
pression induction therapy using thymoglobulin. Recently we 
experienced prolonged insulin independence after single donor 
islet cell transplantation [40,41]. The patient has been insulin 
independent for more than 18 months after single islet cell trans-
plantation. In this case, we used thymoglobulin induction with 
potent anti-inflammatory drugs, and the transplanted islet yield 
was 12,200 IEQ/kg body weight [40,41]. This case suggests 
that it is possible to achieve prolonged insulin independence 
with a single donor islet cell transplantation combined with 
immunosuppression induction using thymoglobulin and anti-
inflammatory drug administration.202
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Side effects of immunosuppressants
The side effects of immunosuppressants are a common prob-
lem among all allogeneic transplantations. The Edmonton pro-
tocol has unique problems related to the high dose of sirolim-
us [2,10,42]. High concentrations of sirolimus cause painful 
oral ulcers, peripheral edema, poor wound healing and thin-
ning nails. Those side effects are not life-threatening however; 
the quality of life deteriorates for transplant patients. In addi-
tion, the combination of tacrolimus and sirolimus causes pro-
teinuria and deterioration of renal function [9]. Since one of 
the expected results of islet transplantation is to prevent sec-
ondary diabetic complication including diabetic nephropathy, 
the side effect of poor kidney function is unacceptable. 
  In order to minimize the side effects of immunosuppressants, 
we eliminated sirolimus from our immunosuppression thera-
py after islet transplantation [40,41]. This protocol has dramat-
ically reduced the side effects of immunosuppressants.
FUTURE DIRECTION OF β-CELL 
REPLACEMENT THERAPY FOR TYPE 1 
DIABETES
As mentioned above, all current major drawbacks of islet cell 
transplantation should be solved in near future. Then, islet cell 
transplantation for the treatment of type 1 diabetes will become 
the standard therapy. Donor shortage is the next issue to be 
solved. Marginal donor islet cell transplantation and living do-
nor islet cell transplantation could alleviate the donor shortage. 
Since the number of cadaveric donors for islet cell transplanta-
tion was extremely low in Japan [50], both islet transplants us-
ing marginal donors [34] and a living donor [51,52] were per-
formed in Japan. Therefore, these options could be implement-
ed with the current islet cell transplantation protocol.
  Xeno-islet cell transplantation using pig islets could solve the 
issue of donor shortage. Encapsulated porcine islets [53] and 
porcine islet containing devices [54] were transplanted into 
type 1 diabetic patients. The efficiencies of both clinical trans-
plants were less compared to allogeneic islet cell transplanta-
tion. Further improvements are necessary to expand the effi-
cacy of xeno-islet cell transplantation.
  β-cell regeneration using human stem cells has the potential 
to treat diabetes. The efficacy of β-cell regeneration and the 
safety of generated cells are major issues for their clinical appli-
cation. Kroon et al. [55] demonstrated that pancreatic endo-
derm derived from human embryonic stem cells generated glu-
cose-responsive insulin-secreting cells in vivo. However, none 
of generated β-cells from human stem cells ever reversed dia-
betes in mice. Therefore, improved efficacy is the important 
next step for β-cell generation using stem cells.
  Gene delivery directly to a patient’s pancreas for β-cell re-
generation is an attractive treatment, since no transplantation 
is necessary. Recently, we demonstrated that gene delivery us-
ing micro-bubble destruction technology successfully deliv-
ered NeuroD into the pancreas of diabetic rats and reversed 
diabetes [56]. Further studies including a large animal model 
are necessary to confirm the safety and efficacy; however, this 
shows potential to be the next generation of diabetes treatment. 
AUTOLOGOUS ISLET CELL 
TRANSPLANTATION TO PREVENT 
SURGICAL DIABETES
Autologous islet cell transplantation after a total or semi-total 
pancreatectomy for chronic pancreatitis with severe abdomi-
nal pain is an established treatment [4]. Total pancreatectomy 
effectively reduces abdominal pains even for patients requir-
ing narcotics for the abdominal pains [4,57,58]. While trans-
plantation of autologous islet cells isolated from a pancreas with 
choric pancreatitis can prevent surgical diabetes [4,57,58]. Au-
tologous islet transplants were also applied to total pancreatec-
tomies of benign pancreatic tumors [59] and pancreatic trau-
ma [60].
  The clinical outcome for metabolic control is excellent after 
autologous islet cell transplantation compared to allogeneic islet 
cell transplantation. The differences between the two transplan-
tation therapies are shown in Table 1. The reasons for the favor-
Table 1. Differences between allogeneic islet transplantation 
and autologous islet transplantation
Characteristic Allogeneic Autologous
Diseases Type 1  
diabetes
Surgical  
diabetes
Auto-immunogenicity Yes No
Allo-immunogenicity Yes No
Necessity of anti-rejection drugs Yes No
Pancreas suffered cytokine storms Yes No
Cold ischemic period Variable Short
Storage period after islet isolation Variable Short
Islet progenitor cells  Less  More203
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able results of autologous islet cell transplantation are thought 
to be 1) patients have no auto-immune disease, 2) transplant-
ed islets do not suffer allogeneic rejection, 3) diabetogenic an-
ti-rejection drugs are not required, 4) pancreata do not suffer 
cytokine storms during brain-dead periods, 5) the cold preser-
vation period for retrieved pancreata is short, 6) isolated islets 
are immediately transplanted without culture, and 7) pancrea-
ta from chronic pancreatitis might have more islet progenitor 
cells in their pancreatic ducts [61].
  Even though autologous islet cell transplantation after total 
pancreatectomy is an established therapy for chronic pancre-
atitis with severe abdominal pain, only a limited number of cen-
ters perform this therapy (Fig. 1). The requirements of current 
good manufacturing practice (cGMP) facilities for the clinical 
islet isolation procedure limit the availability of this therapy. 
The cGMP facility is especially expensive due to its maintenance 
requirements, therefore only limited hospitals have such facili-
ties. Recently, successful remote center autologous islet cell trans-
plantation was reported [60]. In this case, the pancreas was sur-
gically removed for the treatment of pancreatic trauma and was 
shipped to the islet isolation center, and then isolated islets were 
sent back to the hospital. In the case of total pancreatectomy 
for chronic pancreatitis, the removed pancreas should be sent 
to an islet isolation center for autologous islet cell transplanta-
tion if the hospital does not have islet isolation facility.
CONCLUSION
Allogeneic islet cell transplantation has dramatically improved 
and is ready to be the standard therapy for the treatment of type 
1 diabetes. Donor shortage is the next issue and can be addressed 
by marginal and/or living donor islet cell transplantation, xeno 
islet cell transplantation and β-cell regeneration.
  Autologous islet cell transplantation is an effective treatment 
for chronic pancreatitis with severe abdominal pain. Remote 
center autologous islet cell transplantation should be consid-
ered when a total pancreatectomy is performed in a hospital 
not possessing an islet isolation center.
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